Navigation Links
Regenetek Research Inc. Launches New Intelligent Software for Therapeutic Stem Cell Trials
Date:12/11/2012

WINNIPEG, Manitoba, Dec. 11, 2012 /PRNewswire/ -- Doug Broeska, Ph.D., CEO of Regenetek Research Inc., an international medical research company with offices in Canada and India has announced that they are launching new web-based, self-managing, clinical trial software that amongst other things will be able to extend patient Registry information into individual patient case studies and aggregate the data with comparisons to cohorts. The company has so far specifically focused their new technology on a number of autologous therapeutic stem cell trials for a range of neurologic diseases that are taking place in multiple centers worldwide. Such software would have important application where limited financial resources are combined with the need to validate efficacy and prove reproducibility of therapy protocols.

"The ability to rigorously evaluate individual patients, monitor adverse events, and aggregate data from different patients in different centers while maintaining ethical standards will achieve better control of bias, generate greater statistical power, and produce more meaningful conclusions for clinical outcomes," says Dr. Broeska, CEO of Regenetek Research. Indeed, for cases where every patient's cells are unique, randomized controlled trials are simply not possible as an appropriate design for clinical investigation.

"This is just getting back to the basics of medical research. A lot of medical investigation used to be done this way," says Broeska. "Many medical breakthroughs were made only through observations with an N of one, but now we have the advantage of being able to handle big data through new technologies. We can chart the outcomes of many individual patient case studies over time, aggregate, and even compare the data in a meaningful way to produce valid evidence. We are not limited to therapeutic stem cell research but that is an obvious place to start. Moving all medical investigation forward, faster is our goal."

Inquiries may be directed to Dr. Doug Broeska at "info@regenetek.com" or call 204-975-9665.

This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Regenetek Research Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Scientific Research & Development in the US Industry Market Research Report from IBISWorld has Been Updated
2. GeneTex Launches New Antibody Against Phosphorylated Histone H3 for Epigenetics Research
3. France & Germany Blood Banking Market: Innovative Technologies and Emerging Business Opportunities in New Research Report at ReportsnReports.com
4. UT Arlington research team wins $1.35 million NSF robotics grant to develop smart skin applications
5. Premier Biomedical Successfully Advances Cancer Research
6. US Natural Polymers Market Forecasts to 2016 in New Research Report at ReportsnReports.com
7. Leuven research opens new pathway for the treatment of Alzheimers disease
8. Industrial carbon management research gets $3.75 million boost
9. Diabetes Research Institute Foundation’s (DRIF) CEO Joins Healthcare Holdings Group, Inc. Board of Directors
10. ArteryHealth.org Launches as a Collective Database of Artery Health Research
11. Research discovery could revolutionize semiconductor manufacture
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... 2016 The report "Acrylic Processing Aid Market by Polymer Type (PVC), ... Goods) - Global Forecast to 2026", published by MarketsandMarkets, the global market size ... Million by 2026, registering an of CAGR of 6.2% between 2016 and 2026. ... ... MarketsandMarkets Logo ...
(Date:12/7/2016)... 2016  Genprex, Inc. a biopharmaceutical company focused ... today announced that it has retained ICR Healthcare, ... communications and advisory firm, to develop and implement ... combine investor relations, public relations and digital communications ... of Genprex and its lead candidate Oncoprex, which ...
(Date:12/7/2016)... ANN ARBOR, Mich. , Dec. 7, ... developing breakthrough immune modulatory medicines, announced today the initiation ... lead therapeutic candidate, LYC-30937- E nteric C oated, ... skin disease that is estimated to affect as many ... , with approximately 1.5 - 3 million cases ...
(Date:12/7/2016)... ... December 07, 2016 , ... Cambrian ... for industrial facilities, today announced that one of the nation’s fastest growing craft ... novel water-energy purchase agreement (WEPA). Under the WEPA, a first for the industrial ...
Breaking Biology Technology:
(Date:12/6/2016)... Ind. , Dec. 6, 2016  Zimmer Biomet Holdings, ... it has priced an offering of €500.0 million principal amount ... million principal amount of its 2.425% senior unsecured notes due ... expected to occur on December 13, 2016, subject to the satisfaction ... an annual basis. The ...
(Date:12/2/2016)... India , December 1, 2016 ... Authentication type (Fingerprint, Voice), Future Technology (Iris Recognition ... and Region - Global Forecast to 2021", published ... USD 442.7 Million in 2016, and is projected ... at a CAGR of 14.06%.      ...
(Date:11/29/2016)... 29, 2016 BioDirection, a privately held medical ... the objective detection of concussion and other traumatic brain ... completed a meeting with the U.S. Food and Drug ... Pre-Submission Package. During the meeting company representatives reviewed plans ... precursor to commencement of a planned pilot trial. ...
Breaking Biology News(10 mins):